UNSPSC 51182018: Androstenediol

This classification denotes an anabolic steroid with the molecular formula C19H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95PS51EMXY, chemically known as 3beta,17beta-dihydroxyandrost-5-ene but generally known as androstenediol, which bears US NIH Compound Identifier 10634. European Medicines Agency schedules Androstenediol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12899MIG. As of Q4 2014, ANDROSTENEDIOL remains the US FDA Preferred Term for this commodity.

Androstenediol bears US NLM identifiers UMLS ID C0524764 and NCI Concept Code C95979. SMILES: OC1C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C..

UNSPSC 51182018 Androstenediol, a Commodity code, identifies a controlled androgenic steroid compound that state and local governments procure primarily through cooperative purchasing agreements for pharmaceutical distribution networks. Recent activity shows this code tagged to broad multi-source pharmaceutical and over-the-counter product contracts rather than single-ingredient procurement; state and local buyers acquire androstenediol as one line item within comprehensive generic pharmaceutical catalogs managed through authorized drug wholesalers and distributed to public facilities including hospitals, clinics, and correctional institutions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing evaluated at 75 percent weight and administrative compliance requirements (cGMP certification, DSCSA compliance, EDI capability, and $5 million to $2 million insurance coverage) at 25 percent combined. Awarded vendors will become effective July 1, 2026, with a two-year initial term and optional extensions; the procurement does not disclose specific budget ranges or set-aside designations. Geographic activity centers on the Upper Midwest and Pacific Northwest through the MMCAP cooperative mechanism, which aggregates demand across multiple state and local purchasing entities to negotiate volume pricing on pharmaceutical catalogs that include controlled and non-controlled generics.